Last reviewed: July 3, 2026
Last updated: July 3, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both tirzepatide and semaglutide have demonstrated significant weight loss results in clinical trials, but they are not identical medications. Understanding their differences—including mechanism of action, efficacy data, and how your genetics may influence response—helps you make an informed decision about which might work better for your body.
How Tirzepatide and Semaglutide Work Differently
Semaglutide is a GLP-1 receptor agonist, meaning it activates one hormone pathway in your brain and gut that controls appetite and blood sugar. Tirzepatide, by contrast, is a dual GIP/GLP-1 receptor agonist—it activates two separate pathways simultaneously. This dual action targets both appetite suppression and metabolic rate through different biological mechanisms, which may explain why some patients experience greater weight loss with tirzepatide.
The GIP receptor pathway, which tirzepatide uniquely engages, plays a distinct role in how your body processes glucose and stores energy. When both pathways are activated together, the combined effect can produce more pronounced changes in appetite signals and energy expenditure. This doesn't mean tirzepatide is universally superior—individual response depends on your genetics, lifestyle, and metabolic profile.
Clinical Trial Results: Weight Loss Outcomes Compared
Semaglutide demonstrated average weight losses of 10–15% of body weight in the STEP trials, with some patients achieving up to 18% reduction over 68 weeks. Tirzepatide showed more substantial results in the SURPASS trials, with average reductions of 20–22% of body weight, and some participants losing up to 24% over similar timeframes. These differences reflect the additional metabolic pathway tirzepatide engages, though individual results vary widely.
It's important to note that higher average weight loss in clinical trials doesn't guarantee better personal outcomes for every individual. Some patients respond powerfully to semaglutide alone, while others achieve their goals faster with tirzepatide. Genetic factors—including variants in the GLP1R, GIPR, FTO, and MC4R genes—influence how strongly your body responds to each medication pathway.
Cost and Access: Compounded Options at PlexusDx
Brand-name Mounjaro (tirzepatide) and Wegovy (semaglutide) carry significant out-of-pocket costs, often $900–$1,500 per month without insurance coverage. PlexusDx offers compounded tirzepatide injection starting at $289/mo (or $249/mo on the 6-month plan) and compounded semaglutide starting at $189 per month—both from licensed 503A compounding pharmacies. Your dose may need to go up. Your price won't. Neither medication requires a membership fee or insurance, and both are HSA/FSA eligible for additional savings.
PlexusDx serves all 50 states and works with licensed compounding pharmacies that meet the same quality and sterility standards as brand manufacturers. Compounded formulations are chemically identical to their brand counterparts but cost a fraction of the price, making sustained treatment more accessible for patients who would otherwise abandon therapy due to cost.
How Your Genetics Relate to GLP-1 Pathways
Your genetic makeup significantly influences how your body responds to tirzepatide versus semaglutide. PlexusDx offers the Precision Peptide Genetic Test—a $99 add-on after your first month of treatment—that analyzes your unique variants in peptide-pathway genes including GLP1R, GIPR, FTO, and MC4R. This test maps 14 metabolic pathways across 49 peptides, providing 150+ personalized insights to guide your treatment selection.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Side Effects and Tolerability: What Patients Experience
Both medications commonly cause gastrointestinal side effects including nausea, vomiting, and constipation, especially during dose escalation. Semaglutide users report these effects in roughly 20–30% of cases at higher doses, while tirzepatide users experience them at similar or slightly higher rates due to its more potent dual-pathway activation. Most side effects diminish after the first 2–4 weeks as your body adapts, and proper dosing timing and hydration strategies significantly reduce severity.
Tirzepatide users occasionally report more pronounced appetite suppression and occasional loose stools, reflecting its stronger metabolic impact. Semaglutide may feel slightly gentler during the initial titration phase. Individual tolerability is highly variable—some patients thrive on tirzepatide's aggressive effect while others prefer semaglutide's more gradual approach. PlexusDx clinicians monitor your response closely and adjust dosing or compound selection if side effects become problematic.
Which Medication Should You Choose?
Tirzepatide is often the preferred first choice for patients seeking maximum weight loss over a shorter timeframe, particularly those with insulin resistance or prediabetes. Semaglutide may be better suited for patients new to GLP-1 therapy who want a gentler introduction, those with a history of GI sensitivity, or individuals whose genetics suggest strong GLP1R pathway activation. Neither is universally 'better'—the best choice is the one that aligns with your medical history, genetic predispositions, and personal goals.
PlexusDx offers both compounded tirzepatide injection (starting at $289/mo (or $249/mo on the 6-month plan)) and compounded semaglutide injection (starting at $189/mo (or $149/mo on the 6-month plan)), as well as dual-action GLP-Squared formulations combining both compounds. Your PlexusDx clinician will review your metabolic profile, genetic test results if available, and treatment preferences to recommend the option most likely to succeed for your body.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Will tirzepatide produce more weight loss than semaglutide for me personally?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, and GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
What is the main difference between tirzepatide and semaglutide at the molecular level?
Semaglutide activates only the GLP-1 receptor pathway, controlling appetite and glucose. Tirzepatide simultaneously activates both GLP-1 and GIP receptors, adding a second metabolic signaling pathway that may enhance weight loss and metabolic rate. This dual action explains tirzepatide's higher average efficacy in clinical trials, though not every patient experiences the benefit equally.
How much less expensive is PlexusDx compounded tirzepatide compared to brand Mounjaro?
PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan), compared to typical brand Mounjaro costs of $900–$1,500 monthly without insurance. PlexusDx covers all 50 states, requires no membership, and formulations are HSA/FSA eligible, delivering savings of 60–80% while maintaining pharmaceutical-grade quality from licensed 503A compounding pharmacies.
Are compounded tirzepatide and semaglutide as safe as brand versions?
Yes. PlexusDx sources all compounded medications from licensed 503A compounding pharmacies, which follow FDA manufacturing standards identical to brand-name facilities. Compounded tirzepatide and semaglutide are chemically equivalent to Mounjaro and Wegovy, with the same safety profiles and efficacy—the primary difference is cost and accessibility.
Can the Precision Peptide Genetic Test tell me which medication will work best for me?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Protecting Your Progress: Do You Need to Refrigerate Your Ozempic Pen?
Is Wegovy Injectable? An In-Depth Look at This Weight Loss Solution